non-alcoholic fatty liver disease

(redirected from Non-alcoholic steatohepatitis)

non-alcoholic fatty liver disease

A fatty liver lacking histologic features typically associated with alcohol abuse, which primarily affects overweight women. With time, patients develop portal changes such as interface hepatitis, increased portal inflammation and fibrosis, and autoantibodies.
Risk factors
Diabetes, obesity, hypertension, gallstones, hyperlipidaemia, hypertriglyceridaemia.

Uncertain; possibly oxidative stress and lack of antioxidants.

Non-alcoholic fatty liver disease types
• Steatosis;
• Steatosis with inflammation;
• Non-alcoholic steatohepatitis (NASH);
• Cirrhosis.
Mentioned in ?
References in periodicals archive ?
NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today reported business highlights and financial results for the third quarter of 2015.
21, 2015 /PRNewswire/ -- Pharmaceutical company Pharmaxis (ASX: PXS) today announced positive results for all primary and secondary endpoints from the phase 1 clinical trial of PXS-4728A, a drug that was recently acquired by Boehringer Ingelheim to develop as a treatment for cardiometabolic diseases such as Non-Alcoholic Steatohepatitis (NASH).
Hepatic oxidative stress plays a key role in the development of non-alcoholic steatohepatitis (NASH), therefore, treatment approaches that address the antioxidant is helpful in the therapy of patients with NASH.
BHV is a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate ("remogliflozin") for type 2 diabetes and non-alcoholic steatohepatitis ("NASH").
One early study of patients with non-alcoholic fatty liver disease, with or without the complication of hepatitis C infection, showed significant reductions in plasma markers of liver fibrosis (the first step towards deadly non-alcoholic steatohepatitis know as NASH), and significant improvements in insulin resistance, using a combination of silybin, vitamin E, and phospholipids.
Food and Drug Administration (FDA) has granted GR-MD-O2 (galactoarabino-rhamnogalacturonate) Fast Track designation for non-alcoholic steatohepatitis (NASH) with hepatic fibrosis, commonly known as fatty liver disease with advanced fibrosis.
This early-stage health condition can sometimes progress to more serious, even fatal diseases, including non-alcoholic steatohepatitis, or NASH.
Recent studies have provided several lines of evidence that could be attributable to the hypothalamus-pituitary-adrenal (HPA) axis alterations in fatty liver disease and non-alcoholic steatohepatitis (NASH) (8-11).
4 Non-alcoholic steatohepatitis (NASH) is the non-benign form of NAFLD potentially leading to liver cirrhosis but also to hepatocellular carcinoma.
The recent study has highlighted its potential in countering an increasingly common kind of fatty liver disease called non-alcoholic steatohepatitis (NASH).
Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), and aldehyde dehydrogenase ("ALDH2") deficiency.
The histological changes of NAFLD are steatosis and non-alcoholic steatohepatitis (NASH).

Full browser ?